Biohaven Ltd. filed its quarterly report on Form 10-Q with the SEC on August 10, 2026, covering the three- and six-month periods ended June 30, 2026, disclosing continued operating losses alongside reduced research and development spending compared to the prior-year period.

Key Highlights

  • Net loss of $137.3 million for the three months ended June 30, 2026, compared to $198.1 million in the same period of 2025, according to the filing.
  • Research and development expenses were $100.8 million for Q2 2026, compared to $184.4 million in Q2 2025, as reported in the condensed consolidated statements of operations.
  • Cash and cash equivalents totaled $238.0 million as of June 30, 2026, up from $230.0 million as of December 31, 2025, per the balance sheet.
  • Accumulated deficit reached $2.352 billion as of June 30, 2026, compared to $2.085 billion at December 31, 2025, according to the filing.
  • 151,017,531 common shares were issued and outstanding as of June 30, 2026, up from 132,775,113 at December 31, 2025, the filing stated.
  • Net cash used in operating activities was $235.0 million for the six months ended June 30, 2026, compared to $333.1 million in the same period of 2025.

Biohaven's Q2 2026 Operations and Pipeline Activity

Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company incorporated in the British Virgin Islands, described itself in the filing as "focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, obesity, neuroscience, and oncology." The company reported total operating expenses of $124.9 million for the three months ended June 30, 2026, compared to $211.7 million in the same period of 2025, driven primarily by changes in research and development costs.

According to the filing, the company's key clinical and preclinical programs include Kv7 ion channel modulation for epilepsy, its MoDE and TRAP extracellular protein degradation platforms for immunological diseases, and a myostatin-activin pathway targeting agent for neuromuscular and metabolic diseases including obesity. The company reported general and administrative expenses of $24.1 million for Q2 2026, compared to $27.3 million in Q2 2025. For the six months ended June 30, 2026, total operating expenses were $255.3 million versus $433.3 million in the first half of 2025.

The balance sheet as of June 30, 2026 showed total assets of $370.7 million and total liabilities of $358.5 million, leaving total shareholders' equity of $12.2 million. Notes payable stood at $259.5 million as of June 30, 2026, compared to $238.9 million at December 31, 2025. The filing also reported that proceeds from the issuance of common shares contributed $178.9 million to financing activities in the first half of 2026. Net loss per share, basic and diluted, was $(0.91) for Q2 2026, compared to $(1.94) in Q2 2025, reflecting the higher weighted average share count of 150,636,620 versus 102,372,820 in the prior-year quarter.

What Was Disclosed

The filing disclosed Biohaven's unaudited condensed consolidated financial statements for the quarter and six months ended June 30, 2026, covering operating expenses, net losses, balance sheet positions, and cash flow activity, along with a description of the company's therapeutic pipeline and business focus.